Top 10 Companies in the Poly(Lactic-co-Glycolic Acid) (PLGA) Microsphere for Controlled Drug Release Market (2026): Market Leaders Driving Innovation

MARKET INSIGHTS

Global Poly(Lactic-co-Glycolic Acid) (PLGA) Microsphere for Controlled Drug Release market size was valued at USD 1.87 billion in 2025. The market is projected to grow from USD 2.04 billion in 2026 to USD 4.31 billion by 2034, exhibiting a CAGR of 8.7% during the forecast period.

PLGA microspheres are biodegradable and biocompatible polymeric delivery systems engineered to encapsulate active pharmaceutical ingredients and release them in a controlled, sustained manner over a defined therapeutic window. Composed of co-polymers of lactic acid and glycolic acid, these microspheres undergo hydrolytic degradation in physiological environments, enabling precise modulation of drug release kinetics. Their applications span a broad therapeutic spectrum, including oncology, neurology, endocrinology, and vaccine delivery, making them one of the most versatile platforms in advanced drug formulation science.

The market is witnessing robust expansion driven by the rising global burden of chronic diseases, increasing demand for long-acting injectable formulations, and growing preference for patient-compliant drug delivery systems that reduce dosing frequency. Furthermore, advancements in microencapsulation technologies and the expanding pipeline of PLGA-based pharmaceutical products are reinforcing market momentum. Key industry participants such as Evonik Industries AG, Corbion N.V., Surmodics Pharmaceuticals, and Oakwood Labs continue to invest in proprietary PLGA formulation platforms, strengthening their competitive positioning across global markets.

Download the Sample Report:
Poly(Lactic-co-Glycolic Acid) (PLGA) Microsphere for Controlled Drug Release Market – View in Detailed Research Report

1. Evonik Industries AG

   Headquarters: Essen, Germany
   Key Offering: RESOMER® PLGA polymers, advanced microsphere formulation services.

   Evonik is a global leader in polymer chemistry, providing high-quality PLGA grades under the RESOMER® brand. Its robust R&D portfolio includes tunable lactic-to-glycolic acid ratios and end‑group chemistry, enabling precise control over degradation rates and drug release kinetics. Evonik’s integrated platform spans polymer synthesis, microencapsulation, and GMP‑compliant manufacturing, positioning it as a preferred partner for pharmaceutical companies seeking scalable, regulatory‑ready microsphere solutions.

   Sustainability & Growth Initiatives:

   • Investment in green chemistry processes to reduce solvent usage and waste.
   • Development of biodegradable polymers with lower environmental impact.
   • Strategic partnerships with leading pharma for co‑development of long‑acting injectables.

2. Oakwood Labs (Orient Pharma Sciences)

   Headquarters: San Diego, United States
   Key Offering: Drug‑loaded PLGA microspheres for oncology and CNS indications.

   Oakwood Labs specializes in formulation science and microencapsulation technologies. Their proprietary surface‑modified microspheres enhance targeting and reduce immunogenic clearance, making them ideal for CNS and oncology drug delivery. Oakwood’s expertise in spray‑drying and solvent‑evaporation processes ensures high encapsulation efficiency for hydrophilic therapeutics.

   Sustainability & Growth Initiatives:

   • Expansion of GMP facilities to support global supply chains.
   • Adoption of continuous manufacturing for increased scalability.
   • Collaboration with academic institutions for innovative drug delivery research.

3. GP Pharm

   Headquarters: Madrid, Spain
   Key Offering: End‑to‑end CDMO services for PLGA microsphere development.

   GP Pharm offers comprehensive contract manufacturing, from polymer synthesis to sterile formulation. Their validated processes and ISO certifications support rapid commercialization of PLGA‑based drugs, especially in the EU market where regulatory compliance is stringent.

   Sustainability & Growth Initiatives:

   • Implementation of energy‑efficient manufacturing lines.
   • Use of renewable feedstocks for polymer production.
   • Participation in EU sustainability certification programs.

4. Chong Kun Dang Pharmaceutical

   Headquarters: Seoul, South Korea
   Key Offering: Commercialized PLGA microsphere products for hormonal and peptide therapeutics.

   Chong Kun Dang has successfully launched PLGA‑based depot formulations for LHRH agonists, establishing a strong foothold in the Asian market. Their localized manufacturing reduces supply chain risk and supports rapid time‑to‑market for new indications.

   Sustainability & Growth Initiatives:

   • Investment in cold‑chain infrastructure for biologic stability.
   • Strategic alliances with global pharma for joint development.
   • Adoption of eco‑friendly solvent recovery systems.

5. Particle Sciences (Lubrizol Life Sciences)

   Headquarters: Northbrook, United States
   Key Offering: Advanced microfluidic and spray‑drying platforms for PLGA microspheres.

   Particle Sciences provides cutting‑edge microencapsulation technologies that enable precise particle sizing (1–500 µm) and high drug loading. Their platforms are widely used by biotech companies developing next‑generation biologic and gene therapies.

   Sustainability & Growth Initiatives:

   • Development of scalable continuous manufacturing processes.
   • Partnerships with academic centers for platform innovation.
   • Focus on reducing solvent waste through closed‑loop systems.

6. Coating Place Inc.

   Headquarters: San Diego, United States
   Key Offering: Surface‑modified microspheres and coating technologies.

   Coating Place specializes in functionalizing PLGA surfaces with targeting ligands or stealth polymers to improve biodistribution and reduce immune clearance. Their expertise supports both small‑molecule and biologic drug delivery.

   Sustainability & Growth Initiatives:

   • Investment in green chemistry for coating formulations.
   • Expansion of contract manufacturing to meet global demand.
   • Collaboration with pharma for co‑development of long‑acting biologics.

7. Bachem AG

   Headquarters: Allschwil, Switzerland
   Key Offering: High‑purity PLGA polymers and peptide‑loaded microspheres.

   Bachem is renowned for its pharmaceutical excipients. Their PLGA grades support high‑quality peptide formulations, and they provide analytical services for release testing and IVIVC studies.

   Sustainability & Growth Initiatives:

   • Use of renewable raw materials for polymer synthesis.
   • Implementation of ISO 14001 environmental management.
   • Development of low‑energy manufacturing processes.

8. Aurobindo Pharma Ltd.

   Headquarters: Ahmedabad, India
   Key Offering: Large‑scale production of PLGA microspheres for generic biologics.

   Aurobindo has expanded its manufacturing footprint to include PLGA microsphere production, targeting the growing Indian and global generics market for long‑acting injectables.

   Sustainability & Growth Initiatives:

   • Adoption of water‑recycling systems in production.
   • Partnerships with local universities for talent development.
   • Investment in cold‑chain logistics for biologic stability.

9. Vetter Pharma

   Headquarters: Munich, Germany
   Key Offering: Advanced PLGA microsphere formulation and scale‑up services.

   Vetter’s expertise in high‑grade polymers and GMP manufacturing supports rapid development of complex drug products, including gene‑based therapies and vaccines.

   Sustainability & Growth Initiatives:

   • Implementation of renewable energy in manufacturing sites.
   • Continuous improvement of solvent recovery.
   • Collaboration with pharma for sustainable drug delivery solutions.

10. Corbion N.V.

    Headquarters: Utrecht, Netherlands
    Key Offering: Sustainable PLGA polymers and co‑encapsulation technologies.

    Corbion focuses on bio‑based polymers and offers innovative co‑encapsulation strategies that improve drug loading and reduce burst release, enhancing the performance of PLGA microspheres.

    Sustainability & Growth Initiatives:

    • Use of renewable feedstocks for polymer production.
    • Development of low‑carbon manufacturing processes.
    • Strategic alliances with pharma for sustainable delivery platforms.

Download FREE Sample Report: Poly(Lactic-co-Glycolic Acid) (PLGA) Microsphere for Controlled Drug Release Market – View in Detailed Research Report

Get Full Report Here: Poly(Lactic-co-Glycolic Acid) (PLGA) Microsphere for Controlled Drug Release Market – View in Detailed Research Report

OUTLOOK

The PLGA microsphere market is poised for sustained growth, driven by the global shift toward long‑acting injectable therapies and the increasing prevalence of chronic diseases. Regulatory clarity from the FDA and EMA, coupled with advances in microencapsulation technologies, will lower barriers to entry and accelerate product commercialization. The Asia‑Pacific region is expected to capture the fastest growth, supported by expanding biopharmaceutical manufacturing capacity and rising healthcare expenditures.

FUTURE TRENDS

• Proprietary PLGA formulation platforms that enable precise tuning of degradation rates.
• Integration of PLGA microspheres with biologics, RNA therapeutics, and gene‑editing tools.
• Single‑dose, thermostable vaccine delivery systems leveraging controlled antigen release.
• Continuous, scalable manufacturing processes that reduce cost and time to market.
• Enhanced sustainability initiatives focusing on renewable feedstocks and solvent‑recycling.